Sylvester Comprehensive Cancer Center

  • 20221112 - Franzmann Elizabeth

  • Investigator:
    Elizabeth Franzmann
    RCname Email

    		Coordinator:

    IRB: 20221112

    		SDG: Head and Neck
    Disease Site(s):

    Lip, Oral Cavity and Pharynx
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Doral
    Gables
    Plantation
    Sylvester
    Title:

    Phase II A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia
    Eligibility Criteria - NCT05865028 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221146 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    		Coordinator:

    IRB: 20221146

    		SDG: Head and Neck
    Disease Site(s):

    Multiple
    Sponsor: BioNTech SE

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester
    UMH
    Title:

    An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
    Eligibility Criteria - NCT04534205 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230991 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    		Coordinator:

    IRB: 20230991

    		SDG: Head and Neck
    Disease Site(s):

    Multiple
    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
    Eligibility Criteria - NCT05063552 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230134 - Olazagasti Coral

  • Investigator:
    Coral Olazagasti
    RCname Email

    		Coordinator:

    IRB: 20230134

    		SDG: Head and Neck
    Disease Site(s):

    Multiple
    Sponsor: NRG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Protocol NRG-HN009, Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Eligibility Criteria - NCT05050162 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240355 - Rich Benjamin

  • Investigator:
    Benjamin Rich
    RCname Email

    		Coordinator:

    IRB: 20240355

    		SDG: Head and Neck
    Disease Site(s):

    Multiple
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    RADIOACTIVE Radiotherapy Patient Education with Virtual Reality
    Eligibility Criteria - NCT06506435 *This information has been extracted from " www.clinicaltrials.gov"